Center for Scientific Review; Notice of Closed Meetings, 30965-30966 [2021-12144]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 110 / Thursday, June 10, 2021 / Notices
aimed at reducing cells infected with
HIV.
Inventors: Jason Brenchley and
Charlotte Langner, both of NIAID.
Publications: Langer, Charlotte A. and
Brenchley, Jason M.; Frugally
Optimized DNA Octomer (FRODO)
qPCR Measurement of HIV and SIV in
Human and Nonhuman Primate
Samples; Current Protocols, 2021.
Intellectual Property: HHS Reference
No. E–024–2021; US Provisional
Application No. 63/128,392.
Licensing Contact: To license this
technology, please contact Benjamin
Hurley at 240–669–5092 or
benjamin.hurley@nih.gov, and reference
E–024–2021.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize this invention. For
collaboration opportunities, please
contact Benjamin Hurley; 240–669–
5092, benjamin.hurley@nih.gov.
Dated: June 2, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2021–12181 Filed 6–9–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKJM1Z7X2PROD with NOTICES
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Summer Institute for Biostatistics.
Date: July 15, 2021.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
17:15 Jun 09, 2021
Jkt 253001
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Shelley Sehnert, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Suite 208–T,
Bethesda, MD 20817, (301) 827–7984,
ssehnert@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: June 4, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–12140 Filed 6–9–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Computational, Modeling and
Biodata Management.
Date: July 6, 2021.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Marie-Jose Belanger, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm 6188, MSC
7804, Bethesda, MD 20892, (301) 435–1267,
belangerm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Oncology.
Date: July 7–8, 2021.
Time: 9:00 a.m. to 7:00 p.m.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
30965
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Nywana Sizemore, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6189,
MSC 7804, Bethesda, MD 20892, 301–408–
9916, sizemoren@csr.nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Biostatistical Methods and Research Design
Study Section.
Date: July 7–9, 2021.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Victoriya Volkova,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3140,
Bethesda, MD 20892, (301) 594–7781,
victoriya.volkova@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Synthetic and Biological
Chemistry.
Date: July 7–8, 2021.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Shan Wang, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, (301) 496–4390,
shan.wang@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Oral and Dental Sciences.
Date: July 7, 2021.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Chee Lim, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 4128, Bethesda, MD 20892,
(301) 435–1850, limc4@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Biostatistical Methods and Research Design.
Date: July 7, 2021.
Time: 1:30 p.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Karen Nieves Lugo, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm. 3148,
MSC 7770, Bethesda, MD 20892, (301) 594–
9088, karen.nieveslugo@nih.gov.
E:\FR\FM\10JNN1.SGM
10JNN1
30966
Federal Register / Vol. 86, No. 110 / Thursday, June 10, 2021 / Notices
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cancer Detection and Therapy.
Date: July 7, 2021.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Laura Asnaghi, Ph.D.,
Scientific Review Officer, National Institutes
of Health, Center for Scientific Review, 6701
Rockledge Drive, Room 6200, MSC 7804,
Bethesda, MD 20892, (301) 443–1196,
laura.asnaghi@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 4, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–12144 Filed 6–9–21; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Collaborative Research Projects (PAR–18–
951).
Date: July 21, 2021.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Rajiv Kumar, Ph.D.,
Branch Chief, Blood and Vascular Branch,
Office of Scientific Review/DERA, National
Heart, Lung, and Blood Institute, 6705
Rockledge Drive, 208–W, Bethesda, MD
20892, 301–827–4612, rajiv.kumar@nih.gov.
17:15 Jun 09, 2021
Dated: June 4, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–12141 Filed 6–9–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Benjamin Hurley; tel. 240–669–5092;
benjamin.hurley@nih.gov. Licensing
information may be obtained by
communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852; tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
Producing Modified Vaccinia Ankara
(MVA) Virus with Continuous
Mammalian Cell Lines: Viral Host-range
Factors for Increasing MVA Vaccine
Production Yield Description of
Technology:
Modified vaccinia Ankara (MVA)
based vaccines are being deployed in
numerous human clinical trials for
indications such as measles, malaria,
HIV–1 and MERS to name a few. As
with many vaccines, scale-up and
production are significant challenges
with the MVA platform. Not only are
current large-scale MVA vaccine
production processes inefficient (such
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Jkt 253001
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
as the cumbersome use of chick embryo
fibroblast (CEF) cells), but a major
bottleneck lies in limited host cell
propagation options and a lack of viable
continuous cell lines suitable for MVA
vaccine production.
To address this need, scientists at
NIAID have identified a number of key
viral factors in MVA replication in
mammalian cells and developed
methods of modifying MVA viruses in
a way that allows for the growth of MVA
in cells that were previously considered
unsuitable for such purpose. For
example, NIAID scientists observed that
the introduction of a serine protease
inhibitor 1 (SPI–1) gene into the MVA
genome led to more than a 2-log
enhancement of virus spread in human
diploid MRC–5 cells, whereas deletion
of the gene diminished the spread of
host-range extended viruses by similar
extents. Additionally, MRC–5 cells
stably expressing SPI–1 also enhanced
replication of MVA.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Vaccine Development: Recombinant
MVA-based vaccine production in nonCEF cell lines.
• Therapeutic oncolytic virus:
Recombinant MVA constructs encoding
oncolytic tumor-suppressor proteins,
pro-apoptotic proteins, cytokines,
immunomodulatory proteins, cytotoxic
peptides, suicide proteins, cytotoxins,
pro-drugs, therapeutic RNAs, etc.
Competitive Advantages:
• Recombinant MVA constructs for
use in non-avian, continual cell linemediated vaccine production.
• Efficient scale-up vaccine
production as a result of higher viral
yield, enhancing epidemic/pandemic
preparedness.
Inventors: Bernard Moss, Linda Wyatt,
Ruikang Liu, Jorge Mendez-Rios, all of
NIAID.
Publications:
Liu R, Mendez-Rios JD, Peng C, et al. SPI–
1 is a missing host-range factor required
for replication of the attenuated modified
vaccinia Ankara (MVA) vaccine vector in
human cells.; PLoS Pathog. 2019.
Peng C, Moss B. Repair of a previously
uncharacterized second host-range gene
contributes to full replication of
modified vaccinia virus Ankara (MVA)
in human cells. Proc Natl Acad Sci U S
A. 2020.
Intellectual Property: HHS Reference
No. E–076–2019; International
Application No. PCT/US20/33788.
Licensing Contact: To license this
technology, please contact Benjamin
E:\FR\FM\10JNN1.SGM
10JNN1
]]>Agencies
[Federal Register Volume 86, Number 110 (Thursday, June 10, 2021)]
[Notices]
[Pages 30965-30966]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-12144]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Computational, Modeling and Biodata
Management.
Date: July 6, 2021.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Marie-Jose Belanger, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm 6188, MSC 7804, Bethesda, MD 20892,
(301) 435-1267, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Fellowships: Oncology.
Date: July 7-8, 2021.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Nywana Sizemore, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6189, MSC 7804, Bethesda, MD
20892, 301-408-9916, [email protected].
Name of Committee: Population Sciences and Epidemiology
Integrated Review Group; Biostatistical Methods and Research Design
Study Section.
Date: July 7-9, 2021.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Victoriya Volkova, Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3140, Bethesda, MD 20892, (301) 594-7781,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Fellowships: Synthetic and Biological Chemistry.
Date: July 7-8, 2021.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Shan Wang, Ph.D., Scientific Review Officer,
Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 496-4390, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Oral and Dental Sciences.
Date: July 7, 2021.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Chee Lim, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4128, Bethesda, MD 20892, (301) 435-1850,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Biostatistical Methods and Research Design.
Date: July 7, 2021.
Time: 1:30 p.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Karen Nieves Lugo, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm. 3148, MSC 7770, Bethesda, MD
20892, (301) 594-9088, [email protected].
[[Page 30966]]
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Cancer Detection and Therapy.
Date: July 7, 2021.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Laura Asnaghi, Ph.D., Scientific Review Officer,
National Institutes of Health, Center for Scientific Review, 6701
Rockledge Drive, Room 6200, MSC 7804, Bethesda, MD 20892, (301) 443-
1196, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: June 4, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-12144 Filed 6-9-21; 8:45 am]
BILLING CODE 4140-01-P
